Momenta Pharma announces aNDA for generic Copaxone accepted for review by FDA
Momenta Pharmaceuticals announced the FDA has accepted for review the Abbreviated New Drug Application for a three-times-a-week generic COPAXONE® (glatiramer acetate injection, 40 mg/mL), submitted by Sandoz, Momenta's development and commercialization partner for this product candidate. August 28, 2014